Lamivudine Plus Zidovudine Compared with Zalcitabine Plus Zidovudine in Patients with HIV Infection: A Randomized, Double-Blind, Placebo-Controlled Trial

Annals of Internal Medicine

Volumn 125, Issue 3, 1996, Pages 161-172

  Bartlett, John A ^b   Benoit, Sharon L ^a,c   Johnson, Victoria A ^f   Quinn, Joseph B ^d   Sepulveda, Gladys E ^g   Ehmann, W Christopher ^h   Tsoukas, Chris ⁱ   Fallon, Mary Ann ^a,c   Self, Pamela L ^e   Rubin, Marc ^e  

^a Division of Virology   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c University Corporate Center Inc   (United States)

^d Medco Research Inc   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g Hospital Regionale de Ponce   (Puerto Rico)

^h PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

ⁱ MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA 2 MICROGLOBULIN; BIOPTERIN; DRUG DERIVATIVE; GAG PROTEIN; LAMIVUDINE; NEOPTERIN; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; GENETICS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; METABOLISM; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BETA 2-MICROGLOBULIN; BIOPTERIN; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; NEOPTERIN; POLYMERASE CHAIN REACTION; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; ZALCITABINE; ZIDOVUDINE;

EID: 0030215471     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-3-199608010-00001     Document Type: Article

References (42)

1. Concorde: MRC/ANS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet. 1994;343:871-81.
2. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH Jr, Reichman RC, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994;272:437-42.
3. Hammer S, Katzenstein D, Hughes M, Gundacker H, Blaschke T, Schooley R, et al. Nucleoside monotherapy vs. combination therapy in HIV-infected adults: A randomized, double-blind, placebo-controlled trial in persons with CD4 cell counts 200-500 per cubic millimeter. N Engl J Med. [In press].
4. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-4.
5. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3:743-6.
6. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1996;373:117-22.
7. 4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-6.
8. Johnson VA. Combination therapy: more effective control of HIV type 1? AIDS Res Hum Retroviruses. 1994;10:907-12.
9. Meng TC, Fischl MA, Boota AM. Spector SA, Bennett D, Bassiakos Y, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med. 1992;116:13-20.
10. Collier AC, Coombs RW, Fischl MA, Skolnik PR, Northfelt D, Boutin P, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med. 1993;119:786-93.
11. Yarchoan R, Lietzau JA, Nguyen BY, Brawley OW, Pluda JM, Saville MW, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis. 1994;169:9-17.
12. Kojima E, Shirasaka T, Anderson BD, Chokekijchai S, Steinberg SM, Broder S, et al. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis. 1994;171:1152-8.
13. Fiscus SA, DeGruttola V, Gupta P, Katzenstein DA, Meyer WA 3d, LoFaro ML, et al. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter trial. J Infect Dis 1995;171:305-11.
14. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med. 1995;122:24-32.
15. Coates JA, Cammack N, Jenkinson HJ, Jowett AJ, Jowett MI, Pearson BA, et al. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother. 1992;36:733-9.
16. Schinazi RF, Chu CK, Peck A, McMillan A, Mathis R, Cannon D, et al. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother. 1992;36:672-6.
17. Cammack N, Coates JA, Jenkinson HI, Rouac J, Penn CR, Cameron JM. (-) Enantiomeric 2′-deoxy-3′-thiacytidine (3TC): a potent and selective anti-HIV agent that acts in synergistic combinations with other inhibitors of HIV [Abstract]. In: VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, 19-24 July 1992: PuA6036.
18. Viner KC, Cammack N, Coates JA, Hooker EU, Rouse P, Penn CR, et al. Levoenantiomeric 2′ deoxy-3′-thiacytidine 3TC in combination with AZT synergistically inhibits clinical isolates of HIV-1 [Abstract]. In: 9th International Conference on AIDS. Berlin, Germany, 1993. Berlin: Institute for Clinical and Experimental Virology of the Free University of Berlin: 1993: Po-A25-0607.
19. van Leeuwen R, Lange JM, Hussey EK, Donn KH, Hall ST, Harker AJ, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992;6:1471-5.
20. van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995;171:1166-71.
21. Pluda JM, Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1995;171:1438-47.
22. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 1993;90:5653-6.
23. Gao Q, Gu Z, Hiscott J, Dionne G, Wainberg MA. Generation of drug-resistant variants of the human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′- dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1993;37:130-3.
24. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine (3TC) in vitro is due to one amino acid change substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37:2231-4
25. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993;37 875-81.
26. Schuurman R, Nijhuls M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-9.
27. Larder BA, Kemp SD, Harrigan R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269: 696-9.
28. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adults and Adults. MMWR. 1992; 41(RR-17):1-19.
29. Dawson JD. Comparing treatment groups on the basis of slopes, areas under-the-curve, and other summary measures Drug Info J. 1994;28:723-32.
30. van Elteren P. On the combination of independent two sample tests of Wilcoxon. Bull Inst Intl Stat. 1960;37:351-61.
31. Berry DA. Statistical Methodology in the Pharmaceutical Sciences. New York: Marcel Dekker: 1989.
32. Collier AC, Coombs RL, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-7.
33. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995;333:1662-9.
34. 3 [Abstract]. Presented at the Second National Conference on Human Retroviruses and Related Infections, Washington, DC, 2 February 1995:LB32.
35. 3 [Abstract]. Presented at the Second National Conference on Human Retroviruses and Related Infections, Washington, DC, 2 February 1995;LB31.
36. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426-31.
37. Hooper C, Welles S, D'Aquila RT, Japour A, Johnson V, Kuritzkes DR, et al. HIV-1 RNA level in plasma and association with disease progression, zidovudine sensitivity phenotype and genotype, syncytium-inducing phenotype, CD4+ cell count and clinical diagnosis of AIDS [Abstract]. Presented at the Third International Workshop for HIV Drug Resistance, Kauai, Hawaii, 2-5 August 1994.
38. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Johnson VA, et al. Prognostic capacity of plasma HIV-1 RNA copy number in ACTG 116A [Abstract]. Presented at the 2nd National Conference on Human Retroviruses, Washington, DC, 29 January-2 February 1995: 230.
39. Hammer S. Virologic markers and outcome in ACTG 175 [Abstract]. Presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996:S24.
40. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992;326:437-43.
41. Kuritzkes D, Bell S, Shugarts D, et al. Development of resistance to lamivudine (3TC) in NUCA 3001, a phase II comparative trial of 3TC vs zidovudine (ZDV) vs 3TC plus ZDV [Abstract]. Presented at the Second National Conference on Human Retroviruses and Related Infections, Washington, DC, 2 February 1995:LB36.
42. Wakefield JK, Jablonski AS, Morrow CD. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol. 1992;66:6806-12.